Dr. Lawrence S. Honig, Professor of Neurology at the CUIMC, comments on the significance of Food and Drug Administration approval of the Alzheimer’s disease drug, Lecanemab
Mitchell S.V. Elkind, MD, MS, MPhil, Professor of Neurology & Epidemiology, comments on the new study & recommendation of taking daily baby aspirin to help prevent first-time heart attack or stroke
Lawrence S. Honig, MD, PhD, Professor of Neurology at the CUIMC, an investigator for the study that led to the FDA’s approval of Leqembi expresses his opinions about the new Alzheimer’s Disease drug
Joshua Z. Willey, MD, Associate Professor of Neurology at the CUIMC, comments on the risk-benefit of using aspirin by patients with no heart attack or stroke history
Andrew B. Lassman, MD, Professor of Neurology & Associate Dean of Clinical Trials at Columbia University, talks about the importance of enrolling a diverse population of subjects in clinical trials
Jennifer J. Manly, PhD, Professor of Neuropsychology, and Lawrence S. Honig, MD, PhD, Professor of Neurology, comment on donanemab, the second Alzheimer’s drug
Carol M. Troy, MD, PhD, Professor of Pathology & Cell Biology and Neurology at CUMC, and colleagues led a study that found eye drop treatment alternative to Retinal vein occlusion (RVO) disease
Lawrence S. Honig, MD, PhD, a professor of neurology at CUIMC, estimates that group constitutes about a sixth of the more than 6 million Americans currently diagnosed with Alzheimer’s
Jennifer J. Manly, PhD, a Professor of Neuropsychology in Neurology at CUIMC spoke with The New York Times about the complicated legacy of affirmative action.
